We are committed to serving the best interests of our shareholders. The investor pages that follow are your resource for financial information about Catalyst Biosciences, Inc.
NASDAQ: CBIO$10.490.56 (5.64%)Dec 15, 20174:00 p.m. ET
Delayed at least 15 minutes
Data provided by Nasdaq. Minimum 15 minutes delayed.
Press ReleasesDecember 14, 2017Catalyst Biosciences Announces Appointment of Edward Williams to its Board of DirectorsDecember 09, 2017Catalyst Biosciences Announces Interim Phase 1/2 CB 2679d/ISU304 Results at the American Society of Hematology ConferenceNovember 28, 2017Catalyst Biosciences Strengthens Clinical Hemophilia Programs with Additions to its Senior Leadership TeamView all press releases »
Reverse Stock Split
|For the 1 for 15 Reverse Stock Split Tax Form, click here|
Targacept Special Dividend
|For the FAQ and additional information, click here.|
Catalyst Biosciences, Inc.
Red House Consulting, LLC